Clinical Trials Browser

INDUSTRY × Graft vs Host Disease × 1 year × Clear all

NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

MyeloidOther hematologic neoplasmOther neoplasm

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT02386800 2026-03-16

CINC424A2X01B Rollover Protocol

Phase 4 Active not recruiting

279 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 3 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Phase 4 Active not recruiting

297 enrolled

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease